ID   LiPSC-ER2.1
AC   CVCL_RL62
DR   Wikidata; Q54902572
RX   PubMed=26411904;
RX   PubMed=27283945;
CC   From: Lonza, Inc.; Basel; Switzerland.
CC   Population: Caucasian.
CC   HLA typing: A*03,24; B*27,27; C*01,05; DQB1*03,05; DRB1*01,11 (PubMed=27283945).
CC   Omics: Transcriptomics; Microarray.
CC   Omics: Variations; Array-based CGH.
CC   Derived from site: In situ; Umbilical cord blood; UBERON=UBERON_0012168.
ST   Source(s): PubMed=27283945
ST   Amelogenin: X
ST   CSF1PO: 10,13
ST   D13S317: 11
ST   D16S539: 11,12
ST   D18S51: 12
ST   D21S11: 24.2,30.2
ST   D3S1358: 16,18
ST   D5S818: 11,13
ST   D7S820: 8,10
ST   D8S1179: 14,15
ST   FGA: 22,23
ST   Penta D: 9
ST   Penta E: 10
ST   TH01: 8,9.3
ST   TPOX: 8,9
ST   vWA: 16
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
OI   CVCL_RL63 ! LiPSC-ER2.2
OI   CVCL_RL64 ! LiPSC-ER2.3
SX   Female
AG   <1D
CA   Induced pluripotent stem cell
DT   Created: 05-03-18; Last updated: 10-04-25; Version: 7
//
RX   PubMed=26411904; DOI=10.1016/j.stemcr.2015.08.015; PMCID=PMC4624993;
RA   Baghbaderani B.A., Tian X.-H., Neo B.H., Burkall A., DiMezzo T.,
RA   Sierra G., Zeng X.-M., Warren K., Kovarcik D.P., Fellner T., Rao M.S.;
RT   "cGMP-manufactured human induced pluripotent stem cells are available
RT   for pre-clinical and clinical applications.";
RL   Stem Cell Reports 5:647-659(2015).
//
RX   PubMed=27283945; DOI=10.1007/s12015-016-9662-8; PMCID=PMC4919381;
RA   Baghbaderani B.A., Syama A., Sivapatham R., Pei Y., Mukherjee O.,
RA   Fellner T., Zeng X.-M., Rao M.S.;
RT   "Detailed characterization of human induced pluripotent stem cells
RT   manufactured for therapeutic applications.";
RL   Stem Cell Rev. Rep. 12:394-420(2016).
//